Clinical Trial Detail

NCT ID NCT02608385
Title Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Chicago
Indications

renal cell carcinoma

lung non-small cell carcinoma

Advanced Solid Tumor

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.